

Australian Government

Department of Health and Ageing

Schedule of Pharmaceutical Benefits

for Approved Pharmacists and Medical Practitioners

Effective from 1 May 2004



SCHEDULE OF PHARMACEUTICAL BENEFITS FOR APPROVED PHARMACISTS AND MEDICAL PRACTITIONERS

OPERATIVE FROM 1 MAY 2004
(ALL PREVIOUS EDITIONS CANCELLED)

PHARMACEUTICAL BENEFITS

This Schedule will take effect on 1 May 2004 and all previous issues are cancelled. Remaining Schedules in 2004 will take effect on 1 August and 1 December. Thereafter the Schedule will take effect on 1 April, 1 August and 1 December each year.

Change of Address

Notification of change of address should be directed to the Pharmaceutical Branch, Health Insurance Commission, GPO Box 9826, in your Capital City, or telephone 132 290.

Internet


The Schedule of Pharmaceutical Benefits is also available on the Department of Health and Ageing's internet site at www.health.gov.au.


The address of the Schedule is http://www1.health.gov.au/pbs/index.htm.

Fees, Patient Contributions and Safety Net Thresholds							
The following fees, patient contributions and safety net thresholds apply as at 1 May 2004 and are included, where applicable, in prices published in the Schedule—							
Dispensing Fees:	Ready-prepared Dangerous drug fee Extemporaneously-prepared	\$4.66 \$2.61 \$6.63					
Additional Fees (for safety net prices):	Ready-prepared Extemporaneously-prepared	\$0.93 \$1.32					
Patient Co-payments:	General Concessional	\$23.70 \$3.80					
Safety Net Thresholds:	General Concessional	\$726.80 \$197.60					
Safety Net Card Issue Fee:		\$7.05					

SUMMARY OF CHANGES ADDITIONS

Additions — Items






Additions - Brands



CARDIOVASCULAR SYSTEM —cont.

Code	Name, Restriction, Manner of administration and form	Max. Qty		Premium	Dispensed Price for Max.Qty \$	Maximum Recordable Value for Safety Net \$	Proprietary Name and Manufacturer	
	METOPROLOL SUCCINATE <u>Authority required</u> Moderate to severe heart failu include an ACE-inhibitor if tol			nts stabi	lised on co	nventional	therapy which m	ust
8732N	Tablet 23.75 mg (controlled release)	15	••	••	22.90	23.70	Toprol-XL 23,75	AP
8733P	Tablet 47.5 mg (controlled release)	30	5	••	69.31	23.70	Toprol-XL 47.5	AP
8734Q	Tablet 95 mg (controlled release)	30	5	••	85.47	23.70	Toprol XL 95	AP
8735R	Tablet 190 mg (controlled release)	30	5	**	105.78	23,70	Toprol-XL 190	AP



GENERIC /PROPRIETARY INDEX

Toprol-XL 23.75 (AP)	114
Toprol-XL 47.5 (AP)	114
Toprol-XL 47.5 (AP) Toprol-XL 95 (AP) Toprol-XL 190 (AP)	114
Toprol-XL 190 (AP)	114